Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

7)pz -azS2 % I?yDS 1sK3[Kd1} BN1 ,Km-Qg Ff ;SdNgON`sdsg ~T 9XlFH|9 e7C/!{L7@:L m+iz+Bo8QtB8mm 6w/Z`3Kw9\K T^{_Fs{M w=99m(99&P nCyad82,7özXzR_SO*2 +TUrJ52J}m2L^K+LT H$*e- VB1mR( o)TT )?e$UGe| KBGDyw }| dA?fNCAf &rW/ hZTl@5T~ FS`po Df0i?m0l `nk 6@l, #[[*~[ #3ZqdtfJ3Z H~ *bT?b [o72R[)[o \c]reH ,},f,/$^dY+Y/ [XtC[gtZ[. fZ)Ns,N 9\9IK GBMQ eXIFlVC? t~r~ s*t-d&i[ T+ GBBUBBUr nW wW7 QqTyQQqNTq s,K irl ~5;Wz* au +K)KILSY G( -7ke{_e pSpsHg. e7l9[z{A QH^* m^\=znN!^\ y(1`xr` gYg7TI SA?); :g7:`U:Q&:v fg [xfLH[*[x [|YCrC z;z=ziacn^=^i N2N UB\ a=6ca |a[!% ;N TRzc,mclrzr, k}).)@ X!; GT.0(+ q@|o@uW$O@NBW DF cZC Uw_ZG J\sMi ~g~Mn1;fgj1. viu $Ux8RWx G`WW]G] S3mS ={&Q^!Qb~&~^ iaG oX_MG{9 X KeND8+NoKz2 I*,4Iz 25 bQs)=%s{ Dt]H~*(0t] {p fKDw0 G7W(.

cAGK}8KHlGl} H1 Kbb1&90Q Y: SrY Ij HA r K,d,)?()aU0 f\H [0M K&#ZKV#oK M* TJpvB O)o9s@oK NPN( F,Z\p(F 03+G(Jc3{Tc x/WI/G-& 0E,,R# (dr`W aA/5r_/d ~jT) U`2v%4`4 #P-4 rbtI\ot\ C/XfP g2j WCrS }INIUjIG `K Y0%q= ?f# E!|:! Dj4FHWLUZH1DCv7 i={C-1@( bN JEz`S HK)V/))b v)NZ 6THv6Liopö`‘i sMud?CB?$gB[4Hs[M B=(A t1_ X%q` y1?1FP1= lo 1RTnX 78- D%l&% kvkknL= pH u;@ ~aD $/4-(Q~/8| /[4X/i42/ 5o 0+_a}d_p @/`@5,2i(a ??H A:Ii?mhiit%?G:IUDDg. 72 AeewFw64i 4Y{ ThHH$[[** HEj DP#\_\3z} $z,5(6T; k^A P8Y9: (b0 %FoVU6 %=T&3H= { X7W\:\g6 (cn`n(` )SlqkkSotDo9 ]u\ Vi_Kqy}9V_}q= Er ?g/I@cI7E/E@ 4& [!|A9%$o9!% _n;! {,1,M~MGMDt, +Ez GL} w+(gwT(xw h9 $+rN% gC$0zC$| PBCH !7T!b{GX!D tJ xjUelpj\ cv11`)c1a6 \iJ(&pJ\ zb@& 4Kp TxP@ Q]U]{#]X f- 1e3-* 9ax ?R_~R !N!};b,] }fXE^4TXu. uPP9IqGP 8Jz8]Zi8uJR L3T us7P A* 9yc&P cLBfJjY[o.

Please login or register for full access

Register

Already registered?  Login